Earnings Call Summary | Inari Medical(NARI.US) Q1 2024 Earnings Conference
Earnings Call Summary | Inari Medical(NARI.US) Q1 2024 Earnings Conference
The following is a summary of the Inari Medical, Inc. (NARI) Q1 2024 Earnings Call Transcript:
以下是稻荷醫療公司（NARI）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Inari Medical reported Q1 2024 revenue of $143.2 million, representing an increase of over 23%.
Gross margin for the quarter was 86.8%, decreasing from 88.2% year-on-year due to increasing costs from international expansions and product launches.
Operating expenses of $141.5 million for Q1 2024 evidenced increases from $107.8 million in Q1 2023, primarily due to product portfolio expansion, especially LimFlow.
Q1 2024 posted a net loss of $24.2 million, a significant increase from a loss of $2.2 million in Q1 2023.
The company raised its annual guidance by $10 million at the midpoint, reflecting strong business momentum from VTE and emerging therapies, and growth in international markets.
稻荷醫療報告稱，2024年第一季度收入爲1.432億美元，增長超過23％。
由於國際擴張和產品發佈的成本增加，該季度的毛利率爲86.8％，低於同比的88.2％。
2024年第一季度的運營支出爲1.415億美元，較2023年第一季度的1.078億美元有所增加，這主要是由於產品組合的擴大，尤其是LimFlow。
2024年第一季度淨虧損爲2,420萬美元，較2023年第一季度的220萬美元虧損大幅增加。
該公司在中點將年度預期提高了1000萬美元，這反映了VTE和新興療法的強勁業務勢頭以及國際市場的增長。
Business Progress:
業務進展：
Inari anticipates attaining consistent operating profitability by the first half of 2025.
Intentions are to increase adoption of differentiated toolkits by penetrating deeper within the US market, accessing new markets with its emerging therapies portfolio, and expanding into Japan and China.
Expansion plans include access to sizable new patient populations such as Chronic Venous Disease and Acute Limb Ischemia.
Solid adoption of PE and VTE therapies likens the operational strength of the VTE Excellence initiative.
Inari is on track for a limited market release and the launch of their second-generation Artix system in 2024.
The company's LimFlow product is progressing speedily, with integration expected to be completed in 2025 and reimbursement arrangements under NTAP to be in place by October 2024.
The company continues to expand its commercial footprint across markets with a more focused scope and new leadership on board.
Inari Medical plans to persist in investing in the FlowTriever and ClotTriever products, specifically on enhancing safety, efficacy, and ease of use.
Inari預計，到2025年上半年將實現穩定的運營盈利能力。
意圖是通過更深入地滲透美國市場、憑藉其新興療法產品組合進入新市場以及向日本和中國擴張來提高差異化工具包的採用率。
擴張計劃包括接觸大量新患者群體，例如慢性靜脈疾病和急性肢體缺血。
PE 和 VTE 療法的穩步採用比作 VTE 卓越計劃的運營實力。
Inari有望在市場上限量發佈並在2024年推出第二代Artix系統。
該公司的LimFlow產品進展迅速，整合預計將於2025年完成，NTAP下的報銷安排將在2024年10月之前到位。
該公司繼續擴大其在各個市場的商業足跡，業務範圍更加集中，並加入了新的領導層。
稻荷醫療計劃繼續投資FlowTriever和ClotTriever產品，特別是在提高安全性、有效性和易用性方面。
More details: Inari Medical IR
更多詳情： 稻荷醫療 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。